Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

54 results about "Secreting cell" patented technology

Secretions in humans can be produced by a single cell or by a group of cells commonly called a gland. Some secretions perform special functions in the body (true secretions); others are eliminated as waste products (excretions). Digestive secretions include saliva, gastric juice, intestinal juice, pancreatic juice, and bile.

Bispecific antibodies and uses thereof

The invention provides a bispecific antibody targeting CD3 and MICA and an application of the bispecific antibody. The present invention relates to a conjugate comprising: a first antigen binding region comprising an anti-CD3 antibody or an antigen binding fragment thereof; the present invention relates to an anti-CD3 antibody or an antigen-binding fragment thereof, comprising a first antigen-binding region having MICA binding activity, a second antigen-binding region having MICA binding activity, the anti-CD3 antibody or the antigen-binding fragment thereof comprising a first heavy chain variable region having a specific CDRs amino acid sequence and a first light chain variable region. The bispecific antibody disclosed by the invention can be combined with CD3 and MICA so as to promote T cell activation, secrete cell factors and effectively promote PBMC (peripheral blood mononuclear cells) to kill tumor cells, so that the bispecific antibody has good anti-cancer activity; moreover, the bispecific antibody has reduced proinflammatory cytokine secretion promotion performance and T cell activation promotion performance, is higher in safety, and has good clinical application value and drug development value.
Owner:HEFEI TG IMMUNOPHARMA CO LTD

Application of ICOSL agonist in preparation of vaccine

The invention discloses an application of an ICOSL agonist in preparation of a vaccine, and discovers that under the condition of follicular helper T cell (TFH) defect, ICOS protein is used as the ICOSL protein agonist, and a nanoparticle vaccine coupled with the ICOSL agonist can activate ICOSL molecules and directly act on ICOSL to promote B cell proliferation and anti-apoptosis related gene expression. Antibody reaction and antibody secreting cell differentiation and proliferation can be efficiently promoted; according to the present invention, the ICOS protein-coupled vaccine is prepared by using the ICOS protein as the carrier, and the coupled ICOS protein molecule targets the ICOSL signal channel, such that the strong protection effect is provided in the anti-new crown and HIV virus vaccines, and the good immune effect is provided especially for the immunodeficiency / insufficiency population.
Owner:SUN YAT SEN UNIV

Cell implant including biodegradable porous microwell with stem cell-derived insulin-secreting cell aggregate supported therein, and use thereof

PendingUS20260076997A1Metabolism disorderPancreatic cellsInsulin Secreting CellPancreatic hormone
The present disclosure relates to a transplantable cell therapy product composition for diabetes mellitus that contains an aggregate of insulin-secreting cells derived from stem cells. In the present disclosure, an NF microwell array membrane was fabricated by applying a molding process to an electrospun, permeable, biodegradable polycaprolactone (PCL) NF membrane and thus allows gases and soluble factors to permeate therethrough. The NF microwell of the present disclosure could provide more nutrients to the iPSC aggregates than conventional impermeable PDMS microwells, thus enhancing survival and differentiation capabilities of the cells. Additionally, the NF membrane was attached singly to the subcutaneous tissue and to the surface of organs such as liver and peritoneum without the need for a fixing material or separate sutures and was integrated with surrounding tissues, resulting in higher insulin secretion than PDMS microwells. Therefore, the present disclosure can be effectively utilized as a composition for the prevention or treatment of diabetes.
Owner:POSTECH ACADEMY INDUSTRY FOUNDATION +2

Method for purifying ovarian progenitor cells and application of ovarian progenitor cells in generating steroid secreting cells in vitro

The invention provides a method for purifying ovarian progenitor cells and application of the ovarian progenitor cells to in-vitro generation of steroid secretion cells, and belongs to the technical field of biology. The method for purifying the ovarian progenitor cells comprises the following steps: digesting, filtering and washing an ovary, purifying through a magnetic bead or flow cytometry sorting procedure, and screening to obtain the ovarian progenitor cells, a marker used in the purification process is LY6A, LGR5 or PDGFRA (Platelet Derived Growth Factor Receptor A). Experimental results show that the PDGFRA < + > progenitor cells and the LY6A < + > progenitor cells can form androgen synthetic cells for expressing CYP11A1 and CYP17A1; and the LGR5 < + > progenitor cells can only form progestational hormone synthetic cells which express CYP11A1 but do not express CYP17A1.
Owner:THE SECOND HOSPITAL AFFILIATED TO WENZHOU MEDICAL COLLEGE

Compositions and methods for differentiating b lineage and protein secreting cells

Methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells are disclosed. The methods can involve stage-specific differentiation from stem cells or stem cell-derived hematopoietic progenitor cells through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein producing or protein secreting B cells.
Owner:CANADIAN STEM CELL TECH CO

Compositions and methods for differentiating b lineage and protein-secreting cells

Disclosed are methods and compositions for generating B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells. The methods may relate to stage-specific differentiation from stem cells or stem-cell derived hematopoietic progenitors through one or more intermediates to B lineage cells, such as plasmablasts, plasma cells, and protein-producing or protein-secreting B cells.
Owner:STEMCELL TECHNOLOGIES CANADA INC

Viral subunit vaccines

Described herein is an engineered viral subunit vaccine encoding ASFV capsid proteins (e.g., P72 and Penton) for use in pigs. The vaccine with either P72 or Penton tested in mice elicited significantly higher levels of antigen-specific IgM and IgG, increased frequency of antibody-secreting cells in the bone marrow, and higher quality germinal centers in the spleens of immunized mice. Enhanced T cell responses were also observed, with higher levels of IFN-γ and TNF-α in splenocytes. Immunogenicity assessments in pigs further supported these findings, with both MB-P72 and MB-PN180Q inducing robust B cell and T cell responses. These findings show that expression of capsid proteins P72 and Penton in membrane-bound forms via mRNA preserves their native multimeric structure and enhances their immunogenicity and provides a basis for an effective ASFV vaccine.
Owner:MASSACHUSETTS INST OF TECH

An NPQ-IgG2 / Fc fusion protein and its application

ActiveCN118852468BAntibody mimetics/scaffoldsPeptide/protein ingredientsBeta-cell FunctionInsulin Secreting Cell
This application provides an NPQ-IgG2 / Fc fusion protein and its applications. The fusion protein comprises an NPQ polypeptide and a human IgG2 / Fc region. The NPQ-IgG2 / Fc fusion protein has the ability to specifically bind to hepatocyte HEPG2 and insulin-secreting cells INS-1, and after binding to cells, it undergoes endocytosis, activating intracellular signaling pathways. This application also discloses that the NPQ-IgG2 / Fc fusion protein, through multi-target effects including promoting hepatocyte glucose and lipid metabolism and improving pancreatic β-cell function, can be used to treat liver diseases including fatty liver, diabetes, and other metabolic diseases related to glucose or lipid metabolism disorders.
Owner:SHANGHAI INNOGEN PHARM TECH CO LTD

An inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells

ActiveCN117165516Bhigh activityImprove value-added capabilitiesCulture processCell culture mediaErythroid cellSecreting cell
The present application belongs to the field of biomedicine, and relates to an inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells is based on a human mesenchymal stem cell serum-free culture medium, and is composed of the following components in a mass concentration ratio: bone morphogenetic protein-4 20-60 mg / L, bone morphogenetic protein-7 20-60 mg / L, tretinoin 2-8 mg / L, resveratrol 2-8 mg / L, icariin 2-8 mg / L, benzamide 2-8 ug / L, chloroplatinic acid hexahydrate 2-8 ug / L, ethanolamine 2-8 ug / L, erythropoietin 2-10 ug / L, and vascular endothelial growth factor 2-10 ug / L. The inducer for inducing mesenchymal stem cells to differentiate into estradiol-secreting cells has high induction efficiency.
Owner:QINGDAO RESTORE BIOTECHNOLOGY CO LTD

Anti-topo ii alpha protein monoclonal antibody and preparation method and application thereof

The present application relates to a kind of monoclonal antibody that can identify human Topo II alpha antigen, secretes cell strain, its preparation method and its use in immunodetection.The above technical solution selects the amino acid of 1301-1531 of Topo II alpha protein as antigen peptide, codon optimization becomes the gene fragment suitable for expression in escherichia coli BL21, and finally the recombinant protein includes Topo II alpha protein fragment and histidine protein label.The recombinant protein is immunized to mouse, is fused by cell, screening and subcloning, and obtains mouse hybridoma cell strain, and the anti Topo II alpha protein monoclonal antibody secreted by the cell strain is obtained.The antibody obtained by the present application has high specificity, sensitivity, and can specifically recognize the cell expressing Topo II alpha protein, and is suitable for immunological detection, especially immunohistochemical detection.
Owner:FUZHOU MAIXIN BIOTECH CO LTD

B-type influenza virus T3 peptide fragment capable of inducing cellular immune response and application of B-type influenza virus T3 peptide fragment

The invention discloses an influenza B virus T3 peptide fragment capable of inducing cellular immune response and application of the influenza B virus T3 peptide fragment, and belongs to the technical field of immunotherapy and immunodetection. According to the invention, detection is carried out through ELISpot, and the immunogenicity of the long peptide (SEQ ID NO.1, named as T3) is verified in 21 volunteers. The result shows that the T3 is detected to be positive in four persons, and the positive rate is 19.05%; the IFN-gamma secretory cells of the human PBMCs are detected through ELISpot, and the immune response induced by the T3 in people can reach up to 2870 SFC / 106 PBMC. Therefore, the polypeptide has good immunogenicity and crowd universality, can be used as a specific detection peptide for monitoring the cellular immune level, can effectively activate the T cell immune response of the crowd, and has the potential of being used as a candidate vaccine epitope peptide to be applied to novel vaccine design.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT +1

A method for inducing stem cells to generate insulin-secreting cells and stem cell culture medium

ActiveCN119874929BPancreatic cellsCulture processInsulin Secreting CellStem cell culture
The present invention provides a method and culture medium for inducing the generation of insulin-secreting cells from stem cells using a specific culture medium and method. This method precisely regulates each stage of differentiation, improving differentiation efficiency and yielding more functional insulin-secreting cells. These cells can be used in diabetes research and treatment, providing a valuable reference and application for subsequent diabetes treatments.
Owner:UNITED BIOENGINEERING (SHANDONG) CO LTD

Derivation of glucose-responsive insulin-secreting cells and organoids from human stomach cells and their use to treat diabetes

PendingEP4531873A4Diabetes mellitusInsulin Secreting Cell
The present disclosure is directed to a method of producing human gastric insulin-secreting (GINS) cells and human gastric insulin-secreting (GINS) organoids. The present disclosure provides a population of human gastric insulin-secreting (GINS) cells and a preparation of human gastric insulin-secreting (GINS) organoids, which are glucose-responsive and insulin-secreting. The present disclosure also provides methods of controlling glycemia in a human subject by transplanting to the human subject the population of human GINS cells or the preparation of human GINS organoids.
Owner:CORNELL UNIVERSITY

Specific antibodies targeting tumor necrosis factor receptor superfamily factor 7

The invention discloses a specific antibody targeting tumor necrosis factor receptor superfamily Factor 7. The specific antibody comprises a heavy chain variable region, and the heavy chain variable region comprises complementarity determining regions CDR1, CDR2 and CDR3 of amino acid sequences shown as SEQ ID No.2, SEQ ID No.4 and SEQ ID No.6. The invention further discloses a detection method of the heavy chain variable region. The specific antibody provided by the invention has high affinity and specificity. The CAR-T cell constructed by adopting the specific antibody can specifically recognize tumor cells, secrete cell factors IFN-gamma and efficiently kill the tumor cells.
Owner:HUADAO (SHANGHAI) BIOPHARMA CO LTD

Derivation of glucose-responsive insulin-secreting cells and organoids from human stomach cells and their use to treat diabetes

PendingUS20250367240A1Gastrointestinal cellsMetabolism disorderInsulin Secreting CellPancreatic hormone
The present disclosure is directed to a method of producing human gastric insulin-secreting (GINS) cells and human gastric insulin-secreting (GINS) organoids. The present disclosure provides a population of human gastric insulin-secreting (GINS) cells and a preparation of human gastric insulin-secreting (GINS) organoids, which are glucose-responsive and insulin-secreting. The present disclosure also provides methods of controlling glycemia in a human subject by transplanting to the human subject the population of human GINS cells or the preparation of human GINS organoids.
Owner:CORNELL UNIVERSITY

Stomach body three-dimensional organoid culture medium as well as preparation method and culture method thereof

The invention discloses a stomach body three-dimensional organoid culture medium as well as a preparation method and a culture method thereof, and belongs to the technical field of organoid culture. The stomach body three-dimensional organoid culture medium comprises a basic culture medium and a stomach body organoid growth supplement, the stomach body organoid growth supplement comprises a Wnt signaling pathway agonist, an FGF (Fibroblast Growth Factor) family member, a TGF-beta signaling pathway inhibitor, hyaluronic acid and retinoic acid. The invention further discloses a preparation method of the gastric body three-dimensional organoid culture medium and a gastric body three-dimensional organoid culture method. The method can solve the problems that the existing organoid culture technology is difficult to effectively maintain and amplify the stomach organoid with the functional oxyntocytes, and the existing organoid culture technology has unstable pedigree and incomplete structure.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

Application of intestinal microbial metabolite in preparation of medicine for preventing and treating parasitic infection

The invention relates to application of intestinal microbial metabolites in preparation of drugs for preventing and treating parasitic infection. The invention discloses an intestinal flora metabolite (desaminotyrosine, DAT), which can be used for enhancing a type 2 immune response and preventing and treating infection of parasites. The DAT is mainly an important phenolic acid product generated by metabolism of flavonoid compounds by clostridium, in a Nipostrongylus brasiliensis (Nb) infection model, the metabolite effectively relieves clinical symptoms of mice and promotes proliferation of Tuft cells during parasite infection, the Tuft cells can secrete IL-25 after being proliferated in mice normally drinking the DAT, and in addition, the Tuft cells can secrete IL-25 after being proliferated in the mice normally drinking the DAT. The Tuft cell-derived IL-25 further activates type 2 innate lymphoid cells (ILC2) to generate type 2 immune factors (IL-4 and IL-13), and proliferation of cluster cells accelerates removal of parasites and reduces intestinal injury. In addition, verification is carried out in a cluster cell knockout mouse, and deletion of cluster cells can accelerate proliferation of the Brazilian strongylus nematode and aggravate intestinal injury. The factors are crucial to anti-parasitic reaction of a human body, and the metabolite has a wide application prospect in preparations for preventing and treating parasitic infection.
Owner:XUZHOU MEDICAL UNIVERSITY

Methods of culturing and characterizing antibody secreting cells

This disclosure relates to methods of culturing and characterizing antibody secreting cells. In certain embodiments, this disclosure relates to methods of isolating antibody secreting cells, e.g., long lived plasma cells, replicating the isolated cells in growth media disclosed herein, and determining the nucleic acids sequences in the cells that encode the produced antibodies.
Owner:EMORY UNIVERSITY

Growth inhibitor

An object of the present invention is to provide an approach of removing non-endocrine unintended cells coexisting with insulin-secreting cells obtained by the differentiation. The present invention relates to a method for producing an insulin-producing cell population, comprising the step of treating an insulin-producing cell population obtained by the differentiation from pluripotent stem cells with a PLK inhibitor.
Owner:ORIZURU THERAPEUTICS INC

Differentiation of human embryonic stem cells

InactiveEP4438720A3Pancreatic hormoneEndoderm
The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.
Owner:JANSSEN BIOTECH INC

Method for detecting lactic acid secretion by cells

The present invention relates to a method for detecting single cell lactic acid secretion, and specifically provides a method for detecting cell lactic acid secretion, comprising: 1) incubating a fluorescent probe and cells in separate partitions, and 2) detecting the fluorescent signal, wherein the fluorescent signal of the partition where the lactic acid secreting cell is located is weakened. The method of the present application achieves accurate detection of cell lactic acid secretion.
Owner:SHANGHAI JIAOTONG UNIV

Genetically modified mice for selective depletion of antibody-secreting cells

The disclosure relates to genetically modified non-human animals, including mice, in which a diphtheria toxin receptor (DTR) gene is inserted into the endogenous Jchain locus. Also provided are methods of making the animals, and uses of the animals for selective deletion of antibody-secreting cells (ASCs).
Owner:UNIVERSITY OF SASKATCHEWAN

DC cell culture medium and preparation method thereof

The invention relates to the technical field of cell culture, and particularly provides a DC cell culture medium and a preparation method thereof, and the DC cell culture medium is prepared by mixing 36% by mass of a traditional Chinese medicine extract containing caulis spatholobi, radix zanthoxyli, radix linderae, lucid ganoderma, trametes robiniophila and ginseng with the balance of a complete culture medium. The traditional Chinese medicine extract is combined with the complete culture medium, so that the method focuses on promoting self-repairing of cells and secreting cell factors, reduces the pollution influence of foreign factors and bacteria, and improves the long-term survival rate of mature DC cells.
Owner:LISHAN HEALTH (SHANDONG) GRP CO LTD

Cultured meat compositions

The invention is directed to a method for producing an edible composition, comprising incubating a three-dimensional porous scaffold and a plurality of cell types comprising: myoblasts or progenitor cells thereof, at least one type of extracellular (ECM)-secreting cell and endothelial cells or progenitor cells thereof, and inducing myoblasts differentiation into myotubes.
Owner:ALEPH FARMS LTD

Cell culture medium and cell culture method

The invention discloses a cell culture medium and a cell culture method, and relates to the technical field of immune cell culture. The invention provides a cell culture medium for promoting in-vitro proliferation of NK (Natural Killer) cells. The cell culture medium is prepared from the following components: a DMEM (Dulbecco Modified Eagle Medium) / F12 culture medium, puerarin, butylphthalide, glutamine dipeptide, IL-34 (Interleukin-34), bilobalide and N-acetylcysteine. Puerarin and bilobalide which are added into the cell culture medium have a synergistic effect, so that the multiplication capacity of the NK cells can be improved; butylphthalide added into the cell culture medium is beneficial to improving the NK cell viability, and glutamine dipeptide added into the cell culture medium can remarkably improve the purity of the NK cells; a cell factor content test result also proves that the cell culture medium provided by the invention can also promote the NK cells to secrete cell factors, so that the activity of the NK cells can be improved.
Owner:HAINAN BOAO FUTURE HOSPITAL CO LTD

Culture medium for inducing mesenchymal cells to differentiate into insulin-secreting cells and application of culture medium

PendingCN121950674AImprove induction efficiencyShortened differentiation cycleMetabolism disorderVertebrate cellsInsulin Secreting CellSecreting cell
The invention relates to the technical field of regenerative medicine and cell therapy, in particular to a culture medium for inducing mesenchymal cells to differentiate into insulin-secreting cells and application of the culture medium. By accurately regulating and controlling the oxidation-reduction state of NAD < + > / NADH in cells, the composition proportion of exogenous fatty acid, the dynamic supply concentration of glucose and the anti-oxidative stress level, the differentiation efficiency is remarkably improved, the induction period is shortened, and the method is suitable for industrial production on the premise of not depending on recombinant protein induction factors such as Activin A and Wnt3a. And a mature beta-like cell with stable glucose stimulus dependent insulin secretion (GSIS) capability is obtained. The kit is especially suitable for human adipose tissue-derived mesenchymal stem cells, and can be used as an independent kit product for preclinical research and drug screening of diabetes cell replacement therapy.
Owner:SHENZHEN EDDIE SYNTHETIC BIOTECHNOLOGY CO LTD

Cells capable of secreting factor viii by driving of f8 gene with exogenous promoter

The present disclosure provides isolated induced pluripotent stem cells (iPSCs) having an exogenous promoter operably inserted upstream of a translation initiation region of a gene encoding Factor VIII (FVIII) on genomic DNA, the exogenous promoter being capable of driving the gene to secrete FVIII; a composition comprising the cells; and a pharmaceutical composition comprising FVIII-secreting cells induced from the composition.
Owner:NARA MEDICAL UNIVERSITY +1

Method for specifically mapping antigens to antibody-secreting cells

PendingCN119301454AMicrobiological testing/measurementImmunoglobulinsSecreting cellAntibody-Secreting Cells
The present disclosure provides antibody capture complexes and methods of capturing target antibodies secreted by antibody secreting cells.
Owner:REGENERON PHARMACEUTICALS INC

Method for inducing human adipose-derived stem cells to be differentiated into insulin-secreting cells

The invention discloses a method for inducing human adipose-derived stem cells to be differentiated into insulin-secreting cells. The method comprises the following steps: separating and extracting human adipose-derived stem cells from human adipose tissues and enabling the human adipose-derived stem cells to be self-polymerized; placing the auto-aggregated and balled human adipose-derived stem cells in an induced differentiation medium for first-stage induction to obtain a first induced differentiation system; retinoic acid and a transformation factor beta1 are supplemented into the first induced differentiation system, and meanwhile, synergistic induction is performed in combination with near-infrared light irradiation to obtain a second induced differentiation system; and supplementing taurine, beta cytokine, insulin-like growth factors, nicotinamide and a BMPI type receptor kinase inhibitor into the second induced differentiation system, and carrying out synergistic induction through near-infrared light irradiation to obtain the insulin secreting cells. According to the method, the cell differentiation efficiency is remarkably improved, and a new theoretical basis is provided for differentiation from the human adipose-derived stem cells to the insulin secreting cells and application of the human adipose-derived stem cells.
Owner:SHAANXI ZHUOJIE TIKANG BIOTECHNOLOGY CO LTD

A preparation containing mesenchymal stem cell-derived insulin-secreting cells and use in the preparation of a blood glucose regulating product

ActiveCN121780420BInsulin Secreting CellNiacin
The present application relates to the technical field of biological medicine, in particular to a preparation containing mesenchymal stem cell-derived insulin-secreting cells and application thereof in preparing blood glucose regulating products. The insulin-secreting cells are derived from mesenchymal stem cells, and a four-stage directional differentiation strategy is adopted in the preparation method: in the first stage, all-trans retinoic acid, LDN-193189 and cyclopamine are combined to start endoderm program and specifically inhibit non-target differentiation, so as to realize "lineage locking"; in the second and third stages, high glucose environment and GLP-1 are used to promote the differentiation of cells into endocrine precursors and terminal insulin-secreting cells; in the fourth stage, GLP-1, PTHrP and nicotinic acid are added for "function enhancement", so as to synergistically improve the glucose responsiveness, maturity and anti-reversibility of the cells. The differentiation path of the method is precise and economical in factors, the obtained cells have high insulin positive rate and mature function. The preparation containing the cells can be used for preparing a drug for treating diabetes.
Owner:SHENZHEN EDDIE SYNTHETIC BIOTECHNOLOGY CO LTD